Tunlametinib
 | |
| Clinical data | |
|---|---|
| Trade names | 科露平 |
| Other names | HL-085 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H12F2IN3O3S |
| Molar mass | 491.25 g·mol−1 |
Tunlametinib (trade name 科露平) is a pharmaceutical drug for the treatment of cancer. It is an inhbitor of mitogen-activated protein kinase kinase.[1]
In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.[2][3]
It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.[4]
References
[edit]- ^ "Tunlametinib". NCI Drug Dictionary. National Cancer Institute.
- ^ "Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy". March 18, 2024.
- ^ Keam, Susan J. (2024). "Tunlametinib: First Approval". Drugs. 84 (8): 1005–1010. doi:10.1007/s40265-024-02072-x. PMID 39034326.
- ^ Shi, Yuankai; Han, Xiaohong; Zhao, Qian; Zheng, Yulong; Chen, Jianhua; Yu, Xinmin; Fang, Jian; Liu, Yutao; Huang, Dingzhi; Liu, Tianshu; Shen, Hong; Luo, Suxia; Yu, Hongsheng; Cao, Yu; Zhang, Xi; Hu, Pei (2024). "Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: An open-label, single-arm, multicenter, phase I study". Experimental Hematology & Oncology. 13 (1): 60. doi:10.1186/s40164-024-00528-0. PMC 11167782. PMID 38867257.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |